Henry J. Fuchs - Feb 11, 2022 Form 4 Insider Report for Mirati Therapeutics, Inc. (MRTX)

Role
Director
Signature
/s/ Vickie Reed, Attorney-in-Fact
Stock symbol
MRTX
Transactions as of
Feb 11, 2022
Transactions value $
-$935,777
Form type
4
Date filed
2/14/2022, 03:51 PM
Previous filing
Jan 18, 2022
Next filing
Mar 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Options Exercise $123K +6K +99.65% $20.54 12K Feb 11, 2022 Direct F1
transaction MRTX Common Stock Options Exercise $103K +5K +41.59% $20.54 17K Feb 11, 2022 Direct F1
transaction MRTX Common Stock Sale -$219K -2.09K -12.28% $104.76 14.9K Feb 11, 2022 Direct F1, F2
transaction MRTX Common Stock Sale -$920K -8.7K -58.27% $105.80 6.23K Feb 11, 2022 Direct F1, F3
transaction MRTX Common Stock Sale -$22.3K -210 -3.37% $106.34 6.02K Feb 11, 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRTX Non Qualified Stock Option (right to buy) Options Exercise $0 -6K -100% $0.00* 0 Feb 11, 2022 Common Stock 6K $20.54 Direct F1
transaction MRTX Non Qualified Stock Option (right to buy) Options Exercise $0 -5K -100% $0.00* 0 Feb 11, 2022 Common Stock 5K $20.54 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $104.23 to $105.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $105.28 to $106.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $106.33 to $106.555. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.